Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
The raise comes a month after the Cambridge, Massachusetts-based firm's launch with a $20 million Series A round. Black Diamond is developing drugs that target allosteric mutant oncogenes, which it describes as an unexplored space.
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
The company plans to file an IND for its allosteric HER2-targeting drug at the end of 2019, followed by one for its second product candidate in the first half of 2020.